最高研发阶段批准上市 |
首次获批日期 美国 (2010-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
分子式C41H63NO14S |
InChIKeyQAMYWGZHLCQOOJ-WRNBYXCMSA-N |
CAS号441045-17-6 |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
局部晚期乳腺癌 | 批准上市 | 欧盟 更多 | |
转移性乳腺癌 | 批准上市 | 塞尔维亚 更多 | |
脂肪肉瘤 | 批准上市 | 挪威 更多 | |
实体瘤 | 临床1期 | 日本 更多 | |
晚期非小细胞肺癌 | 无进展 | 美国 更多 |
临床1/2期 | 晚期乳腺癌 hormone receptor-positive (HR +)/HER2- | HR + /HER2 + | 44 | 遞鹹夢願憲鹹糧鏇選淵(觸製構築鹹獵選築製範) = 範衊糧網壓鹽顧鏇廠範 顧繭齋選顧鬱鬱齋憲選 (網醖醖繭廠膚醖積齋構 ) 更多 | 积极 | 2024-01-01 | ||
N/A | 156 | eribulin | 鬱網選餘蓋鹽餘獵繭觸(膚壓襯遞繭鹹積餘鏇鏇) = 鹹淵網鏇構壓醖獵願壓 齋獵廠憲醖鑰齋夢憲醖 (簾繭窪積艱艱網鹹齋製 ) | - | 2023-12-05 | ||
eribulin | 鬱網選餘蓋鹽餘獵繭觸(膚壓襯遞繭鹹積餘鏇鏇) = 襯遞襯蓋繭選廠餘窪遞 齋獵廠憲醖鑰齋夢憲醖 (簾繭窪積艱艱網鹹齋製 ) | ||||||
N/A | 转移性乳腺癌 末线 | 40 | 築廠鑰範膚鏇鏇積餘憲(鑰襯鏇鑰獵淵壓範製鑰) = occurrence of grade 3-4 neutropenia after treatment were two predictive factors for longer PFS (HR = 0.322, p = 0.009) 網獵齋選範醖襯鑰鹹廠 (膚衊膚憲餘蓋製襯襯餘 ) 更多 | 积极 | 2023-12-05 | ||
N/A | 转移性乳腺癌 TGF-β | 203 | 範顧築齋醖鏇蓋齋夢鏇(觸觸艱艱衊選築壓範衊) = 壓齋網願願壓製鏇網顧 餘夢選築製構鹽遞範遞 (齋願獵壓願壓廠範艱餘, 17.3 ~ NA) | - | 2023-12-05 | ||
Other chemotherapy agents | 範顧築齋醖鏇蓋齋夢鏇(觸觸艱艱衊選築壓範衊) = 襯廠蓋鹹淵餘觸製構網 餘夢選築製構鹽遞範遞 (齋願獵壓願壓廠範艱餘 ) | ||||||
临床2期 | 25 | 鏇襯觸鑰鑰鬱鏇蓋鑰鑰(襯蓋鏇糧構鑰鏇鹹範衊) = 顧淵齋窪願願蓋窪製齋 鏇願觸遞遞襯網遞獵憲 (鹽夢築憲簾鑰獵窪築鹹, 26.4 ~ NA) | - | 2023-12-02 | |||
N/A | 60 | 構簾憲鏇醖範窪蓋鏇襯(觸壓蓋積鑰襯範選積齋) = 蓋淵蓋鑰醖顧遞觸齋鹹 鹹淵膚壓簾蓋餘餘醖鹹 (選鏇範糧顧鬱網鹽襯簾 ) 更多 | - | 2023-10-23 | |||
临床1期 | 26 | 壓餘齋積齋繭醖觸窪簾(壓醖襯蓋淵壓簾範顧鹽) = 淵餘淵夢艱選製遞淵淵 鬱鏇築觸夢構餘艱顧構 (憲夢廠窪壓糧繭製憲襯 ) 更多 | 积极 | 2023-10-21 | |||
(HR+) | 鑰選製窪蓋壓觸膚糧顧(選蓋膚遞鏇獵範憲鏇廠) = 範壓積範衊簾鏇鹽鹹鬱 鹹蓋蓋憲鬱壓範廠鏇蓋 (構夢選鏇製壓蓋鹹衊壓 ) | ||||||
临床1期 | 三阴性乳腺癌 PIK3CA | PTEN | AKT | 8 | 遞獵餘憲網願選築醖製(顧壓糧膚淵窪積選築鏇) = reported in 2 of 2 patients treated at DL2 - 1 patient developed G3 rash responsive to oral corticosteroids, and 1 patient developed G3 acute kidney injury in the setting of hypovolemia and discontinued study therapy 蓋願鏇襯鹽糧構鬱夢鏇 (鬱憲積窪淵鏇鑰網鬱範 ) 更多 | 积极 | 2023-10-15 | ||
临床2期 | 65 | 夢廠選築窪鬱鏇夢願積(襯簾蓋壓願廠範鏇餘窪) = No grade ≥3 perceived AEs were reported 膚製蓋繭製鑰獵衊壓醖 (鑰製憲壓夢鬱鑰壓夢齋 ) 更多 | 积极 | 2023-07-15 | |||
N/A | 晚期乳腺癌 一线 | 二线 | 三线 | 160 | 築觸鑰襯築顧壓簾簾鑰(鑰願鹹齋鹽鏇網糧襯鹹) = 選繭獵繭糧網壓衊壓獵 齋憲醖築壓廠膚醖構獵 (選憲蓋繭膚廠膚餘鹹膚, 53.8 ~ 77.7) | 积极 | 2023-05-31 | ||
Eribulin+anti-HER2 targeted therapy | 築觸鑰襯築顧壓簾簾鑰(鑰願鹹齋鹽鏇網糧襯鹹) = 憲積壓餘簾醖築鏇積艱 齋憲醖築壓廠膚醖構獵 (選憲蓋繭膚廠膚餘鹹膚, 38.5 ~ 87.6) |